Key Insights

Highlights

Success Rate

94% trial completion (above average)

Research Maturity

91 completed trials (57% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

3.7%

6 terminated out of 161 trials

Success Rate

93.8%

+7.3% vs benchmark

Late-Stage Pipeline

7%

12 trials in Phase 3/4

Results Transparency

11%

10 of 91 completed with results

Key Signals

10 with results94% success

Data Visualizations

Phase Distribution

89Total
Not Applicable (31)
Early P 1 (6)
P 1 (15)
P 2 (25)
P 3 (9)
P 4 (3)

Trial Status

Completed91
Unknown31
Recruiting12
Withdrawn8
Active Not Recruiting7
Terminated6

Trial Success Rate

93.8%

Benchmark: 86.5%

Based on 91 completed trials

Clinical Trials (161)

Showing 20 of 20 trials
NCT07046442CompletedPrimary

Effect of Pulmonary Rehabilitation and Physical Activity on COVID-19 Long-Term Symptoms (PuReCOVID)

NCT07569523Not Yet Recruiting

Development of Preterm Infants Born During the COVID-19 Pandemic

NCT07287137Phase 4Active Not Recruiting

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

NCT06907251Phase 3Not Yet RecruitingPrimary

Dapagliflozin for Long COVID Syndrome

NCT06871293Not ApplicableRecruiting

Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19

NCT07518771Phase 1CompletedPrimary

PA-001 Ph.1 Study in Healthy and Elderly Subjects

NCT04418206Not ApplicableCompletedPrimary

Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19

NCT06599658Phase 2RecruitingPrimary

COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

NCT06821139Completed

Cohort Study of Intraoperative Lung Protective Ventilation Trends in a Large Canadian Health Authority

NCT07445971Phase 1RecruitingPrimary

A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.

NCT07416539Phase 1RecruitingPrimary

Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19

NCT07412574Early Phase 1CompletedPrimary

Vitamin E Supplementation As Adjunctive Therapy To Lower Inflammation In COVID-19 Patients

NCT07408297Phase 2CompletedPrimary

Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda

NCT07157007Phase 2RecruitingPrimary

Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19

NCT06654973Not ApplicableActive Not RecruitingPrimary

Singapore SARS-CoV-2 Human Challenge Study

NCT07308158Completed

Covid Flu A/B and RSV 4 in 1 Diagnostic Test

NCT07190131CompletedPrimary

Evaluation of COVID-19 and Flu A/B 3 in 1 Combo Rapid Test

NCT07302295Not ApplicableNot Yet Recruiting

Analysis of Suicidal Behavior Among Children and Adolescents in the Auvergne-Rhone-Alpes Region During the Covid 19 Pandemic Period

NCT06831786Early Phase 1CompletedPrimary

Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers

NCT07262450Not ApplicableRecruiting

Assessement of Effectiveness of Seawater Nasal Sprays on Sinonasal Symptoms

Scroll to load more

Research Network

Activity Timeline